ArticleJournal of ovarian research2025
Four-year complete remission with reduced-dose PARP inhibitor in advanced-stage epithelial ovarian cancer harboring a BRCA1 mutation: a case report of a chemotherapy-intolerant patient with idiopathic thrombocytopenic purpura.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOvarian cancer is a type of gynecological malignant tumor with high mortality rate, for which the standard primary treatment consists of cytoreductive surgery followed by platinum-based chemotherapy. However, a common adverse effect of carboplatin-paclitaxel regimen is thrombocytopenia due to bone marrow suppression. For ovarian cancer patients with preexisting idiopathic thrombocytopenic purpura (ITP), there exists a dilemma of balancing oncologic efficacy and hematologic safety. As a targeted therapy, poly ADP-ribose polymerase (PARP) inhibitor is more tolerable to platelet toxicity. CASE PRESENTATION: This report presents a 55-year-old woman with a 20-year history of ITP who was diagnosed with high-grade serous ovarian carcinoma (FIGO stage IIIC). Due to persistent thrombocytopenia, she was unable to tolerate postoperative carboplatin-paclitaxel chemotherapy. Molecular profiling revealed a breast cancer gene 1 (BRCA1) mutation, prompting initiation of olaparib alongside ITP-directed therapy. Over four years of follow-up, the patient achieved sustained tumor remission with stable platelet counts.
conclusionsThis case underscores the potential role of PARP inhibitors as a safe and effective alternative for ovarian cancer patients with concurrent ITP, maintaining both favorable oncologic result and hematologic stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.